Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System

Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System

ABSTRACT Objectives The ALINE trial demonstrated the superiority of alectinib over platinum‐based chemotherapy in resected Anaplastic Lymphoma Kinase (ALK)‐positive non‐small‐cell lung cancer (NSCLC). Considering the high cost of alectinib, this study aimed to evaluate the economic value of alectini...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiran Wei, Yifang Liang, Jiahui Mao, Xin Guan
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Cancer Medicine
Subjects:
adjuvant treatment
alectinib
China
cost‐effectiveness analysis
platinum‐based chemotherapy
Online Access:https://doi.org/10.1002/cam4.70405
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70405

Similar Items